TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Interaction Details
01. General Information
Pair Name Shikonin, 4-hydroxytamoxifen
Phytochemical Name Shikonin (PubChem CID: 479503 )
Anticancer drug Name 4-hydroxytamoxifen (PubChem CID: 449459 )
Structure of
Phytochemical
2D-img
Download
2D MOL 3D MOL
Structure of
Anticancer Drug
2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 284
Pair Name Shikonin, 4-hydroxytamoxifen
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression AKT1 hsa207
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Down-regulation Expression BID hsa637
Up-regulation Cleavage CASP3 hsa836
Up-regulation Cleavage CASP8 hsa841
Up-regulation Cleavage CASP9 hsa842
Up-regulation Expression DIABLO hsa56616
Up-regulation Expression FAS hsa355
Up-regulation Cleavage PARP1 hsa142
Down-regulation Expression PIK3CA hsa5290
Up-regulation Expression ROS1 hsa6098
In Vitro Model MCF-7 Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_0031
MDA-MB-435S Amelanotic melanoma Homo sapiens (Human) CVCL_0622
In Vivo Model Portions of the suspension (6×10⁶ cells in 0.1 mL) were subcutaneously injected into the right flanks of each mouse.
Result The combination of SK and 4-OHT shows highly efficient anticancer effects on breast cancer therapy. SK may be a promising candidate as an adjuvant to 4-OHT for breast cancer treatments, especially for ER- breast cancer.
03. Reference
No. Title Href
1 Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo. Chin Med. 2020 Mar 10;15:23. doi: 10.1186/s13020-020-00305-1. Click
It has been 48368 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP